真菌深部感染发病率的增加,促进了新抗真菌剂的发展及不断地致力于对目前市售抗真菌剂的深入了解。对新三唑类(Itraconazole及Fluconazole)及两性霉素B脂质体剂型的一些最新研究取得了有希望的结果。对那些已有的药物如两性霉素B脱氧胆酸盐、氟胞嘧啶及酮康唑(Ketoconazole)的临床应用及了解尚须作进一步改进。尽管如此,深部真菌感染的治疗,特别是在那些免疫损伤患者中,仍然是很困难的。在抗真菌剂的研究中,主要课题仍然是毒性问题及对其副作用的改善。例如两性霉素B脱氧胆酸盐具有肾毒性。最近的实验室及临床研究证明,用生理盐水使血管膨胀就能够防止或逆转两性霉素B对肾小球过滤速 The increased incidence of fungal deep infections has contributed to the development of new antifungal agents and ongoing commitment to gaining a deeper understanding of the currently marketed antifungal agents. Some recent studies on liposomal formulations of the new triazole (Itraconazole and Fluconazole) and amphotericin B have yielded promising results. The clinical application and understanding of those existing drugs such as amphotericin B deoxycholate, flucytosine and ketoconazole need to be further improved. Nevertheless, the treatment of deep fungal infections, especially in those immune-compromised patients, remains very difficult. In antifungal research, the main issue remains the toxicity issue and its side effects. For example, amphotericin B deoxycholate has nephrotoxicity. Recent laboratory and clinical studies have shown that the expansion of blood vessels with saline can prevent or reverse the effect of amphotericin B on glomerular filtration rate